Oruka Therapeutics
ORKA

Oruka Therapeutics (ORKA) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BTIGMaintainedBuy$151.00Aug 11, 2026
WedbushMaintainedOutperform$165.00Aug 11, 2026
GuggenheimMaintainedBuy$200.00Aug 11, 2026
HC Wainwright & Co.MaintainedBuy$120.00Aug 3, 2026
BTIGMaintainedBuy$151.00Jul 13, 2026
UBSMaintainedBuy$130.00 from $100.00Jul 1, 2026
HC Wainwright & Co.MaintainedBuy$120.00Jun 23, 2026
HC Wainwright & Co.MaintainedBuy$120.00May 18, 2026
BTIGMaintainedBuy$151.00May 14, 2026
HC Wainwright & Co.MaintainedBuy$120.00 from $75.00Apr 29, 2026
BarclaysMaintainedOverweight$160.00 from $78.00Apr 28, 2026
UBSMaintainedBuy$100.00 from $75.00Apr 28, 2026
BTIGMaintainedBuy$151.00 from $78.00Apr 27, 2026
WedbushMaintainedOutperform$85.00 from $45.00Apr 15, 2026
HC Wainwright & Co.MaintainedBuy$70.00 from $40.00Apr 13, 2026
BTIGMaintainedBuy$78.00 from $73.00Apr 13, 2026
GuggenheimMaintainedBuy$125.00Apr 13, 2026
GuggenheimMaintainedBuy$125.00Apr 9, 2026
BarclaysMaintainedOverweight$78.00 from $50.00Apr 7, 2026
GuggenheimMaintainedBuy$125.00 from $60.00Apr 6, 2026

Frequently asked questions

  • What is the latest analyst rating on ORKA?

    On Aug 11, 2026, BTIG maintained Oruka Therapeutics at Buy with a price target of $151.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.